...
首页> 外文期刊>ACS nano >Nanoporous Immunoprotective Device for Stem-Cell-Derived beta-Cell Replacement Therapy
【24h】

Nanoporous Immunoprotective Device for Stem-Cell-Derived beta-Cell Replacement Therapy

机译:用于干细胞衍生的β细胞替代疗法的纳米多孔免疫保护装置

获取原文
获取原文并翻译 | 示例
           

摘要

Encapsulation of human embryonic stem cell-differentiated beta cell clusters (hES-beta C)holds great promise for cell replacement therapy for the treatment of diabetics-without the need for chronic systemic immune suppression. Here, we demonstrate a nanoporous immunoprotective polymer thin film cell encapsulation device that can exclude immune molecules while allowing exchange of oxygen and nutrients necessary for in vitro and, in vivo stem cell viability and function. Biocompatibility studies show the device promotes neovascular formation with limited foreign body response in vivo. The device also successfully prevented teratoma escape into the peritoneal cavity of mice. Long-term animal studies demonstrate evidence of engraftment, viability, and function of cells encapsulated in the device after 6 months. Finally, in vivo study confirms that the device was able to effectively immuno-isolate cells from the host immune system.
机译:人胚胎干细胞分化的β细胞簇(HES-Beta C)的封装对细胞替代治疗进行了巨大的希望治疗糖尿病患者 - 而无需慢性全身免疫抑制。 这里,我们证明了一种纳米多孔免疫保护聚合物薄膜电池包封装置,其可以排除免疫分子,同时允许在体外交换氧气和营养物,并且在体内干细胞活力和功能中。 生物相容性研究表明,该装置促进了体内有限的异物反应的新血管形成。 该装置还成功地防止了畸胎瘤逸出到小鼠的腹膜腔中。 长期动物研究证明了在6个月后封装在装置中的细胞的植入,活力和功能的证据。 最后,在体内研究证实,该装置能够有效地从宿主免疫系统免疫隔离细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号